IXICO plc
("IXICO", the "Company" or the "Group")
Share option award
9 December 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that the Company has issued a total of 1,400,000 share options.
These options are awarded to members of the broader leadership of the Company and have vesting criteria aligned with retention and annual revenue growth over 3 years. These options have an exercise price of £0.01 and will be subject to a hold period to the third anniversary of their award.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Ends
For further information please contact:
| IXICO plc | +44 (0) 20 3763 7499 |
| Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer | |
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
| Giles Balleny (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) | |
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.
The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
